The aim of our study was to evaluate the efficacy and bioavailibility of a commonly used oral furosemide dose (500 mg) compared to a 250 mg intravenous (IV) dose in PD patients with significant residual renal function (urine volume > 100 mL). We also evaluated the immediate blood pressure effect in these patients. The data were obtained from a study we performed for the homologation of a 500-mg dose of furosemide by Health Canada.
BargmanJ.M., ThorpeK.E., ChurchillD.N.Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.JASN2001; 12(10): 2158–62.
2.
FlinnA., LedgerS., BlakeP.Effectiveness of furosemide in patients on peritoneal dialysis.CANNT J.2006; 16(3): 40–4.
3.
Van OldenR.W., GuchelaarH.J., StruijkD.G., KredietR.T., AriszL.Acute effects of high-dose furosemide on residual renal function in CAPD patients.Pent Diallnt2003; 23(4): 339–47.
